JP2016526012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526012A5 JP2016526012A5 JP2016508190A JP2016508190A JP2016526012A5 JP 2016526012 A5 JP2016526012 A5 JP 2016526012A5 JP 2016508190 A JP2016508190 A JP 2016508190A JP 2016508190 A JP2016508190 A JP 2016508190A JP 2016526012 A5 JP2016526012 A5 JP 2016526012A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- carboxy
- butanoyl
- ethoxy
- leu27
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 339
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 260
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 234
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 130
- -1 17-carboxyheptadecanoylamino Chemical group 0.000 claims 84
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 18
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 claims 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 12
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 5
- 150000001408 amides Chemical group 0.000 claims 4
- 229960004666 glucagon Drugs 0.000 claims 4
- 108060003199 Glucagon Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 2
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 108010063919 Glucagon Receptors Proteins 0.000 claims 1
- 102100040890 Glucagon receptor Human genes 0.000 claims 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 1
- 239000013067 intermediate product Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 CC(C)(C(*)=O)NN Chemical compound CC(C)(C(*)=O)NN 0.000 description 5
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13164272.0 | 2013-04-18 | ||
| EP13164272 | 2013-04-18 | ||
| US201361814969P | 2013-04-23 | 2013-04-23 | |
| US61/814,969 | 2013-04-23 | ||
| EP13196656.6 | 2013-12-11 | ||
| EP13196656 | 2013-12-11 | ||
| PCT/EP2014/058084 WO2014170496A1 (en) | 2013-04-18 | 2014-04-22 | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019096049A Division JP2019167361A (ja) | 2013-04-18 | 2019-05-22 | 医療用の安定な遷延性glp−1/グルカゴン受容体コアゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526012A JP2016526012A (ja) | 2016-09-01 |
| JP2016526012A5 true JP2016526012A5 (enExample) | 2017-06-01 |
| JP6594856B2 JP6594856B2 (ja) | 2019-10-23 |
Family
ID=51730843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016508190A Active JP6594856B2 (ja) | 2013-04-18 | 2014-04-22 | 医療用の安定な遷延性glp−1/グルカゴン受容体コアゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9474790B2 (enExample) |
| EP (1) | EP2986313B1 (enExample) |
| JP (1) | JP6594856B2 (enExample) |
| KR (1) | KR20160021758A (enExample) |
| CN (1) | CN105307672B (enExample) |
| AU (1) | AU2014255608B2 (enExample) |
| BR (1) | BR112015025464A2 (enExample) |
| CA (1) | CA2909581A1 (enExample) |
| MX (1) | MX362275B (enExample) |
| MY (1) | MY174727A (enExample) |
| PL (1) | PL2986313T3 (enExample) |
| RS (1) | RS59124B1 (enExample) |
| RU (1) | RU2683039C2 (enExample) |
| SI (1) | SI2986313T1 (enExample) |
| WO (1) | WO2014170496A1 (enExample) |
| ZA (1) | ZA201507010B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY167234A (en) | 2011-09-23 | 2018-08-14 | Novo Nordisk As | Novel glucagon analogues |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| JP2016506401A (ja) | 2012-12-21 | 2016-03-03 | サノフイ | 二重glp1/gipまたは三方glp1/gip/グルカゴンアゴニストとしてのエキセンジン−4誘導体 |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| DK2986313T3 (da) * | 2013-04-18 | 2019-08-12 | Novo Nordisk As | Stabile, protraherendede glp-1/glucagonreceptor-co-agonister til medicinsk anvendelse |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
| PT3155017T (pt) * | 2014-05-28 | 2024-05-14 | Mederis Diabetes Llc | Farmacêuticos peptídicos melhorados para resistência à insulina |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| CR20170293A (es) * | 2014-12-30 | 2017-11-03 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón con estabilidad mejorada |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| TN2017000555A1 (en) | 2015-06-30 | 2019-04-12 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
| MY195199A (en) * | 2016-01-13 | 2023-01-11 | Novo Nordisk As | EGF(A) Analogues with Fatty Acid Substituents |
| FR3050112B1 (fr) | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
| SG11201811697SA (en) | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| AR112760A1 (es) | 2017-07-19 | 2019-12-11 | Novo Nordisk As | Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a) |
| GB201720187D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| FI3735295T3 (fi) | 2018-01-03 | 2024-11-20 | Mederis Diabetes Llc | Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon |
| RU2020136305A (ru) | 2018-05-04 | 2022-05-05 | Ново Нордиск А/С | Производные gip и пути их применения |
| US20200268835A1 (en) | 2019-02-27 | 2020-08-27 | Novo Nordisk A/S | Compounds For Use in NASH |
| GB201908424D0 (en) | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| JP7752619B2 (ja) * | 2020-02-21 | 2025-10-10 | スピットファイア ファーマ エルエルシー | Glp-1rおよびgcgrアゴニスト、製剤、ならびに使用方法 |
| US12171806B2 (en) | 2021-09-28 | 2024-12-24 | Spitfire Pharma Llc | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| IL311411A (en) | 2021-09-15 | 2024-05-01 | Viking Therapeutics Inc | Preparations and methods for the treatment of metabolic and liver disorders |
| TW202346323A (zh) * | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的glp—1及升糖素雙重激動肽 |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| IL93173A0 (en) | 1989-02-01 | 1990-11-05 | Shionogi & Co | Production of glucagon |
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| EP1040827A3 (en) | 1995-09-08 | 2000-10-11 | Novo Nordisk A/S | Use of 2-alkylpyrrolidines for the treatment of diabetes |
| CZ220498A3 (cs) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití |
| EP0923580A1 (en) | 1996-07-26 | 1999-06-23 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
| JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
| DE69723869T2 (de) | 1996-12-31 | 2004-04-22 | Dr. Reddy's Laboratories Ltd. | Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten |
| JP2001518069A (ja) | 1997-05-02 | 2001-10-09 | ドクター・レディーズ・リサーチ・ファウンデーション | 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物 |
| BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| EP1000066A1 (en) | 1997-07-16 | 2000-05-17 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| JP4391597B2 (ja) | 1997-12-02 | 2009-12-24 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 抗糖尿病性、低脂質性及び抗高血圧性を有するチアゾリンジオンとオキサゾリジンジオン誘導体 |
| AU6325599A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU6325799A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| EP1123279A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU6325699A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| US6353018B1 (en) | 1998-10-21 | 2002-03-05 | Novo Nordisk A/S | Compounds, their preparation and use |
| ES2200575T3 (es) | 1998-12-18 | 2004-03-01 | Novo Nordisk A/S | Derivados de 1,2,4-tiadiazina fusionados, su preparacion y uso. |
| WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
| JP2002534511A (ja) | 1999-01-18 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 置換型イミダゾール、それらの調製及び使用 |
| TR200103851T2 (tr) | 1999-04-16 | 2002-04-22 | Dr. Reddy' S Research Foundation | Bir antidiyabetik maddenin yeni polimorfik formları, bunların hazırlanması için işlem ve bunları farmasötik bileşimler |
| WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| WO2000063193A1 (en) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| AU2953699A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| AU3958000A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| JP2002542237A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
| EP1171438A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000064884A1 (en) | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| EP1623994A3 (en) | 1999-05-17 | 2008-07-16 | ConjuChem Biotechnologies Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| SI1180121T1 (en) | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| PT1695983E (pt) | 2000-06-16 | 2009-05-05 | Lilly Co Eli | Análogos do peptídeo-1 do tipo glucagon |
| PT1305301E (pt) | 2000-07-20 | 2005-09-30 | Hoffmann La Roche | Benzeno-acetamidas alfa-acilo e alfa-heteroatomo-substituidas activadoras da glucocinase |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| EP2042196B1 (en) | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| US8048408B2 (en) | 2002-01-16 | 2011-11-01 | Biocompatibles Uk Limited | Polymer conjugates |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| NZ541365A (en) | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| EP1503283A1 (en) | 2003-08-01 | 2005-02-02 | Hewlett-Packard Development Company, L.P. | Data processing system and method |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| RU2333223C2 (ru) | 2003-08-12 | 2008-09-10 | Лайпоксен Текнолоджиз Лимитед | Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 glp-1 유도체 |
| RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| CN101380476A (zh) | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| KR101468345B1 (ko) | 2004-11-12 | 2014-12-03 | 바이엘 헬스케어 엘엘씨 | Fviii의 부위 지향 변형 |
| JP2008531764A (ja) | 2005-02-23 | 2008-08-14 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化及び結合のための活性化シアル酸誘導体 |
| EP1863537A2 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2006103298A2 (en) | 2005-04-01 | 2006-10-05 | Novo Nordisk Health Care Ag | Blood coagulation fviii analogues |
| CA2612063A1 (en) | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| EP1893239A2 (en) | 2005-06-15 | 2008-03-05 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of growth hormone |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| EP1981977B1 (en) | 2006-01-31 | 2015-12-23 | National Research Council Of Canada | Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase |
| EP2471810A1 (en) | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| KR20080108147A (ko) | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 viii |
| US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| AU2007333049B2 (en) | 2006-12-15 | 2014-02-20 | Takeda Pharmaceutical Company Limited | Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life |
| CN101578102B (zh) | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物 |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| US20110177029A1 (en) | 2007-06-04 | 2011-07-21 | Novo Nordisk A/S | O-linked glycosylation using n-acetylglucosaminyl transferases |
| US8460909B2 (en) | 2007-06-15 | 2013-06-11 | National Research Council Of Canada | Engineered versions of polysialyltransferases with enhanced enzymatic properties |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| ES2672770T3 (es) * | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| KR20100061477A (ko) * | 2007-09-11 | 2010-06-07 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드 asn-asp-asp-cys-glu-leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu-oh 단독 또는 펩티드 thr-thr-ser-gln-val-arg-pro-arg-oh와의 배합물의 용도 |
| AU2008323768A1 (en) | 2007-11-09 | 2009-05-14 | Baxter Healthcare S.A. | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| DK2257311T3 (da) | 2008-02-27 | 2014-06-30 | Novo Nordisk As | Konjugerede Faktor VIII-Molekyler |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於gip之混合激動劑 |
| TWI541023B (zh) * | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
| EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| MX2011001031A (es) * | 2008-08-07 | 2011-04-26 | Ipsen Pharma Sas | Analogos de polipeptidos insulinotropicos dependientes de glucosa. |
| JP5785872B2 (ja) | 2008-10-17 | 2015-09-30 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 低度の水溶性ポリマーを含む改変血液因子 |
| AU2008365557A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| PL2370462T3 (pl) | 2008-12-15 | 2015-01-30 | Zealand Pharma As | Analogi glukagonu |
| JP2012518029A (ja) | 2009-02-19 | 2012-08-09 | ノヴォ・ノルディスク・アー/エス | 第viii因子の修飾 |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EA026384B1 (ru) | 2010-01-20 | 2017-04-28 | Зилэнд Фарма А/С | Лечение заболеваний сердца |
| EP2552950A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| JP2013523620A (ja) | 2010-03-26 | 2013-06-17 | ノヴォ ノルディスク アー/エス | 新規のグルカゴンアナログ |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| KR20130086343A (ko) | 2010-06-24 | 2013-08-01 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| WO2012088116A2 (en) * | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| CA2822617A1 (en) * | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| SG192038A1 (en) | 2011-01-20 | 2013-08-30 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| RU2013145013A (ru) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
| DK2694095T3 (en) | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| KR102011924B1 (ko) | 2011-05-18 | 2019-08-21 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| AU2012255116B2 (en) | 2011-05-18 | 2017-05-25 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals |
| UA126465C2 (uk) | 2011-06-10 | 2022-10-12 | Ханмі Сайенс Ко., Лтд. | Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить |
| CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| MX2013015168A (es) * | 2011-06-22 | 2014-03-31 | Univ Indiana Res & Tech Corp | Co-agonista del receptor de glucagon/glp-1. |
| MY167234A (en) | 2011-09-23 | 2018-08-14 | Novo Nordisk As | Novel glucagon analogues |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| WO2015086733A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
-
2014
- 2014-04-22 MY MYPI2015703258A patent/MY174727A/en unknown
- 2014-04-22 RS RS20191031A patent/RS59124B1/sr unknown
- 2014-04-22 EP EP14719715.6A patent/EP2986313B1/en active Active
- 2014-04-22 AU AU2014255608A patent/AU2014255608B2/en not_active Ceased
- 2014-04-22 RU RU2015146600A patent/RU2683039C2/ru active
- 2014-04-22 MX MX2015014408A patent/MX362275B/es active IP Right Grant
- 2014-04-22 CA CA2909581A patent/CA2909581A1/en not_active Withdrawn
- 2014-04-22 KR KR1020157032329A patent/KR20160021758A/ko not_active Withdrawn
- 2014-04-22 SI SI201431291T patent/SI2986313T1/sl unknown
- 2014-04-22 BR BR112015025464A patent/BR112015025464A2/pt not_active IP Right Cessation
- 2014-04-22 PL PL14719715T patent/PL2986313T3/pl unknown
- 2014-04-22 JP JP2016508190A patent/JP6594856B2/ja active Active
- 2014-04-22 CN CN201480034914.8A patent/CN105307672B/zh active Active
- 2014-04-22 WO PCT/EP2014/058084 patent/WO2014170496A1/en not_active Ceased
-
2015
- 2015-08-26 US US14/836,192 patent/US9474790B2/en active Active
- 2015-09-21 ZA ZA2015/07010A patent/ZA201507010B/en unknown
-
2016
- 2016-06-10 US US15/179,316 patent/US9751927B2/en active Active
-
2017
- 2017-08-15 US US15/677,585 patent/US20180044394A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015146600A (ru) | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения | |
| RU2434019C2 (ru) | Ацилированные glp-1 соединения | |
| JP2017536343A5 (enExample) | ||
| JP2008533105A5 (enExample) | ||
| US9012398B2 (en) | Acylated exendin-4 compounds | |
| JP5755398B2 (ja) | 伸長されたglp−1化合物 | |
| JP2013543853A5 (enExample) | ||
| JP6179864B2 (ja) | グルカゴン/glp−1レセプタコ−アゴニスト | |
| AU2004290862B2 (en) | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices | |
| JP2004509079A5 (enExample) | ||
| JP2018506507A5 (enExample) | ||
| RU2016134425A (ru) | Стабильные аналоги глюкагона и их применение для лечения гипогликемии | |
| JP2014529629A5 (enExample) | ||
| JP2015517477A5 (enExample) | ||
| JP2017514801A5 (enExample) | ||
| JP2012529463A5 (enExample) | ||
| JP2016531156A5 (enExample) | ||
| JP2014510739A5 (enExample) | ||
| JP2017502024A5 (enExample) | ||
| JP2007537142A (ja) | アルブミン様物質に結合した新規のglp−1類似物 | |
| JP2018505146A5 (enExample) | ||
| JP2016183177A (ja) | 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物 | |
| JP2018515088A5 (enExample) | ||
| JP2008533104A (ja) | Glp−1受容体の二量体ペプチドアゴニスト | |
| JP2012512903A5 (enExample) |